Memo - Magazine of European Medical Oncology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Essential news of current guidelines: head and neck squamous cell carcinoma
SummarySquamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer and accounts for 890.000 cases 450.000 deaths worldwide annually. HNSCC is a heterogeneous disease affecting mainly elderly patients, who frequently suffer from significant comorbidities. Due to the aggressive tumor biology and high recurrence rates after curative treatment, it is essential to follow the evidence-based treatment recommendations outlined in the international guidelines, although it has to be emphasized that relevant data gaps and controversies exist such as the role of induction chemotherapy, de-intensification s...
Source: Memo - Magazine of European Medical Oncology - October 29, 2022 Category: Cancer & Oncology Source Type: research
The NET G3 enigma: dealing with a “new” entity
The objective of this short review is to summarize pathological characteristics as well as therapeutic data obtained in patients with NET G3. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 25, 2022 Category: Cancer & Oncology Source Type: research
Pharmacokinetic drug interactions of oral anticancer drugs
SummaryOver the past 20 years, oral anticancer drugs have increased in importance for the treatment of solid tumors and hematological diseases. Pharmacokinetic interactions with these drugs are often of clinical relevance. They can occur at the level of absorption, metabolism or excretion. The influence of food on the bi oavailability of drugs—referred to as positive or negative food effect—often requires instruction of the patients about appropriate administration of oral anticancer drugs (e.g., to take a drug in the fasted state or with a meal). The absorption of tyrosine kinase inhibitors, representing weak base...
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
From morphology to molecular targets —the pathologist’s view in diagnosing gastroenteropancreatic neuroendocrine neoplasms
SummaryIn the last decade, a number of genetic alterations in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have been identified. In addition, differences in tumor morphology as well as proliferation index (Ki-67) or number of mitoses have led to changes in the classification of these neoplasms. According to th e new World Health Organization (WHO) classification, GEP-NENs are now divided into two genetically and prognostically different categories: (i) well-differentiated neuroendocrine tumors (NET) subdivided into low (G1), intermediate (2) and high (G3) grade tumors, and (ii) poorly differentiated ...
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
Endometrial cancer: news from ASCO
In conclusion, checkpoint inhibitors ± lenvatinib are now established in the second-line treatment of advanced endometrial cancer. Overall, the inclusion of PD1 or PDL1 inhibitors in systemic treatment regimens offers a significant opportunity for patients whose treatment options i n the past only included conventional chemotherapy, radiotherapy or hormonal therapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
Pharmacokinetic drug interactions of oral anticancer drugs
SummaryOver the past 20 years, oral anticancer drugs have increased in importance for the treatment of solid tumors and hematological diseases. Pharmacokinetic interactions with these drugs are often of clinical relevance. They can occur at the level of absorption, metabolism or excretion. The influence of food on the bi oavailability of drugs—referred to as positive or negative food effect—often requires instruction of the patients about appropriate administration of oral anticancer drugs (e.g., to take a drug in the fasted state or with a meal). The absorption of tyrosine kinase inhibitors, representing weak base...
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
From morphology to molecular targets —the pathologist’s view in diagnosing gastroenteropancreatic neuroendocrine neoplasms
SummaryIn the last decade, a number of genetic alterations in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have been identified. In addition, differences in tumor morphology as well as proliferation index (Ki-67) or number of mitoses have led to changes in the classification of these neoplasms. According to th e new World Health Organization (WHO) classification, GEP-NENs are now divided into two genetically and prognostically different categories: (i) well-differentiated neuroendocrine tumors (NET) subdivided into low (G1), intermediate (2) and high (G3) grade tumors, and (ii) poorly differentiated ...
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
Endometrial cancer: news from ASCO
In conclusion, checkpoint inhibitors ± lenvatinib are now established in the second-line treatment of advanced endometrial cancer. Overall, the inclusion of PD1 or PDL1 inhibitors in systemic treatment regimens offers a significant opportunity for patients whose treatment options i n the past only included conventional chemotherapy, radiotherapy or hormonal therapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 24, 2022 Category: Cancer & Oncology Source Type: research
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), August 6th –9th, 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 21, 2022 Category: Cancer & Oncology Source Type: research
Current standards in the surgical treatment of pancreatic and small intestinal neuroendocrine tumors
SummaryPancreatic and small intestinal neuroendocrine tumors comprise relatively rare and distinctly heterogenous tumor entities which need to be managed quite differently depending on their location, the local and distant tumor extent, hormonal activity, size, and proliferative activity. The best treatment strategy for each subgroup is controversial since evidence from prospective randomized controlled trials is lacking and treatment guidelines are mainly based on results from retrospective studies. Patients with resectable pancreatic neuroendocrine tumors (pNETs) are generally potential candidates for surgical resection,...
Source: Memo - Magazine of European Medical Oncology - October 13, 2022 Category: Cancer & Oncology Source Type: research
